hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06373679 id: Pro00125514 id: 1R01DA056445-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DA056445-01A1 briefTitle: Switch or Quit R01 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-05 date: 2027-05 date: 2024-04-18 date: 2024-04-18 name: Medical University of South Carolina class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: This study evaluates whether non-cigarette tobacco products (e-cigarettes) can help smokers quit smoking as compared to traditional quit methods (nicotine replacement therapy or varenicline/Chantix). Participants in this study will be randomly assigned to one of two groups, then will have a choice between the offered products of that group. Participants in the e-cigarette group will have a choice of e-cigarette brand and flavor. Participants in the medication group will have choice between nicotine replacement therapy (patches and lozenges) or varenicline, also known as Chantix. Participation will last 6 months and will include weekly phone calls for the initial 7-weeks plus a 11-week phone call and a 6-month follow-up visit. Participants will also complete electronic daily diaries during the first 7-weeks. conditions: Cigarette Smoking conditions: Smoking Behaviors studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 225 type: ESTIMATED name: Switching to E-Cigarette name: Switching using Medication measure: Biochemically-confirmed 7-day point prevalence abstinence from cigarettes on timeline followback measure: Greater than 50% reduction in cigarette smoking sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical Univeristy of South Carolina city: Charleston state: South Carolina zip: 29425 country: United States lat: 32.77657 lon: -79.93092 hasResults: False
nctId: NCT06373666 id: SPZ4-02 briefTitle: A Study to Evaluate the Adjustment Function of a Modified Spatz3 Adjustable Balloon (Spatz4). overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-06 date: 2025-06 date: 2024-04-18 date: 2024-04-22 name: Spatz FGIA, Inc class: OTHER briefSummary: The purpose of this study is to evaluate the function of the adjustment procedure with the Spatz4 in subjects with a BMI ≥ 27. conditions: Overweight and Obesity studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Spatz4 Adjustable Balloon System measure: Successful adjustment procedure at 16 ±2 weeks in > 85% of attempts. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373653 id: SOPHMAN-0922/IV briefTitle: Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes. overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2024-06-30 date: 2024-12-30 date: 2024-04-18 date: 2024-04-18 name: Laboratorios Sophia S.A de C.V. class: INDUSTRY briefSummary: This is a phase IV clinical study to demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing restful sensation to the eyes. This will be evaluated by measuring the incidence of unexpected adverse events related to the interventions, the incidence of conjunctival hyperemia and the incidence of sensation of comfort with the application, when applied by the Principal Investigator (PI). conditions: Eye Strain conditions: Eye Strain of Both Eyes studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Phase IV non-inferiority, open-label, controlled, comparative, multicenter, clinical study. primaryPurpose: TREATMENT masking: NONE maskingDescription: Open-label, count: 100 type: ESTIMATED name: Manzanilla Sophia® name: Meticel Ofteno® measure: Analog visual eyestrain test score measure: Incidence of unexpected adverse events related to the interventions measure: Incidence of conjunctival hyperemia measure: Incidence of sensation of ocular dryness. measure: Incidence of ocular irritation measure: Incidence of sensation of (sleep-crust) measure: Incidence of sensation of comfort with the application, when applied by the Principal Investigator (PI) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373640 id: RHM NEU0458 briefTitle: Haemoglobin And Vancomycin Pharmacokinetics in the Cerebrospinal Fluid Following Subarachnoid Haemorrhage acronym: HAPTO overallStatus: NOT_YET_RECRUITING date: 2024-11 date: 2027-03 date: 2028-01 date: 2024-04-18 date: 2024-04-18 name: University Hospital Southampton NHS Foundation Trust class: OTHER briefSummary: The HAPTO study will recruit adult patients with aSAH due to a burst aneurysm. These patients must be scheduled to have their aneurysm treated surgically to prevent further bleeds, and need an external ventricular drain for clinical reasons (to drain fluid and relieve pressure on the brain). At the end of their surgery for their aneurysm, a further drain will be left at the site of the surgery (which is in the basal cisterns) and they will additionally have a drain sited in their lumbar spine. Vancomycin will be given through these drains. Additionally, these drains will allow the fluid in the brain to be collected to measure how haemoglobin levels and vancomycin levels differ between compartments and change over time. Patients will participate in the study over a period from recruitment at three days after aSAH to a maximum of ten days after aSAH. The data will be analysed to determine the relationship in haemoglobin concentrations between different areas of the brain and spine after aSAH, and how vancomycin distribution is related to its route of administration. conditions: Subarachnoid Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 14 type: ESTIMATED name: Insertion of drains name: Vancomycin measure: CSF-haemoglobin concentration sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373627 id: 2024-A00534-43 briefTitle: Procedural Pain Management by Multimodal Sedation Analgesia Combining Hypnosis in Children With Congenital Heart Disease acronym: PEACE-HYPNO overallStatus: NOT_YET_RECRUITING date: 2024-05-02 date: 2025-05-02 date: 2025-05-03 date: 2024-04-18 date: 2024-04-18 name: Fondation Hôpital Saint-Joseph class: OTHER briefSummary: The aim of this prospective randomized controlled trial is to evaluate therapeutic hypnosis as a co-analgesia in thoracic drain removal in children with congenital heart disease. The hypothesis of this study is that therapeutic hypnosis combined with a minimal effective dose of medicated and inhaled sedation-analgesia is not inferior to higher doses of sedation-analgesia usually employed. This would make possible the reduction of cumulative dose of sedative medication and their side effects. conditions: Procedural Pain conditions: Congenital Heart Disease conditions: Heart Surgery conditions: Hypnosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 104 type: ESTIMATED name: Hypnosis name: Conventional medications used for sedation-analgesia name: Medications used in addition to hypnosis measure: Primary Outcome : Pain evaluation by VAS self-assessment measure: Hetero-assessment by FLACC scale of the pain during the intrathoracic drain removal measure: Maximum heart rate measure: Cumulative doses of intravenous analgesics measure: Respiratory depression measure: Parental satisfaction using Visual Analogic Scale (VAS) sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06373614 id: 2023/18 briefTitle: The Effect of Foot Massage and Bed Bath on Individuals With Cancer overallStatus: RECRUITING date: 2023-11-20 date: 2024-05-20 date: 2024-06-20 date: 2024-04-18 date: 2024-04-18 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: Foot massage or bed bath will be applied to improve sleep quality and reduce fatigue levels of individuals with cancer. conditions: Patients studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: foot massage (intervention group) bed bath (intervention group) control (control group) primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 45 type: ESTIMATED name: foot massage name: bed bath measure: sleep quality measure: fatigue sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Health Sciences status: RECRUITING city: Istanbul state: Uskudar country: Turkey name: Ayşe Kabuk, Dr role: CONTACT phone: 05469596616 email: ayse.kabuk@beun.edu.tr name: Ayşe Kabuk, PhD role: CONTACT phone: +905469596616 email: ayseyalili@gmail.com name: Ayşe Kabuk, PhD role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06373601 id: SPAGO briefTitle: SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective acronym: SPAGO overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-02-01 date: 2027-02-01 date: 2024-04-18 date: 2024-04-18 name: Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS class: OTHER briefSummary: The objective of the study is to compare angiographic outcomes of Selution sirolimus coated balloon (MedAlliance) versus SeQuent Please Neo paclitaxel coated balloon (Bbraun) for the treatment of de novo coronary artery lesions in medium size vessels (\>2.00 mm and ≤3.00 mm) with respect to Net Gain (mm) at 12 months follow-up. conditions: Coronary Artery Disease conditions: Stenosis Coronary conditions: Coronary Artery Lesion conditions: Percutaneous Coronary Intervention studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A subject is randomized at a 1:1 ratio either to drug-coated balloon (DCB) angioplasty with a sirolimus-eluting Selution balloon (n=60 subjects) or DCB angioplasty with a paclitaxel-eluting Sequent Please Neo balloon (n=60 subjects). primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: sirolimus-eluting balloon (Selution) name: paclitaxel-eluting balloon (SeQuent Please Neo) measure: In-segment (balloon treated area) Net Gain (mm) at 12 months post-procedure measure: Device success (lesion based) measure: Procedure success measure: Angiographic outcomes 1 measure: Angiographic outcomes 2 measure: Angiographic outcomes 3 measure: Angiographic outcomes 4 measure: Device oriented Composite Endpoint (DoCE/ TLF) measure: Acute/subacute/early/late vessel thrombosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373588 id: MP-37-2023-9418 briefTitle: Patient Navigator Intervention for Migrant Children With Special Healthcare Needs Experiencing Care Transitions overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-05 date: 2027-08 date: 2024-04-18 date: 2024-04-26 name: McGill University Health Centre/Research Institute of the McGill University Health Centre class: OTHER name: Canadian Institutes of Health Research (CIHR) name: Montreal Children's Hospital of the MUHC name: Unity Health Toronto name: The Hospital for Sick Children name: Women's College Hospital name: National Newcomer Navigation Network name: Centre for Refugee Children, Toronto briefSummary: The goal of this randomized controlled trial is to test if a patient navigator program improves healthcare experiences and outcomes for migrant families caring for a child or youth with special healthcare needs (i.e. chronic health condition).
* Fill out questionnaires at 3 time points on barriers to care, caregiver stress, care coordination, and their child's health conditions: Patient Navigation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multi-centre, pragmatic, assessor-blinded, parallel randomized controlled trial with an embedded qualitative study. In the control arm, participants will receive a standard information package and care usually provided within their clinics. In the intervention arm, participants will receive support from a trained patient navigator. The patient navigator will contact participants: 1) Within 7 days of randomization; 2) At least once every 3 months up to 12 months; 3) As needed to follow-up on tasks identified in previous visits; and 4) As initiated by the participant. The navigator will tailor the topics addressed during these interactions according to the needs of the participant and compile a care plan with input from the patient, family, and clinicians. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 324 type: ESTIMATED name: Patient Navigator measure: Barriers to Care (BCQ) measure: Effective care coordination measure: Parental empowerment scale measure: Healthcare utilization measure: PROMIS - Pediatric Global Health 7 measure: Short-form survey 12 measure: Patient Health Questionnaire (PHQ-2) measure: Distress Thermometer measure: Perceived stress scale measure: Patient Satisfaction with Interpersonal Relationships with Navigators (PSN-I) sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Unity Health Toronto, Compass Clinic city: Toronto state: Ontario zip: M5B 1W8 country: Canada name: Ahrrabie Thirunavukkarasu role: CONTACT email: athirun@uwo.ca name: Shazeen Suleman, MD MPH FRCPC role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 facility: Women's College Hospital, Crossroads Clinic city: Toronto state: Ontario zip: M5S 1B2 country: Canada name: Xinyang Ye role: CONTACT email: xinyang.ye@unityhealth.to name: Meb Rashid role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 facility: CLSC de Parc-Extension city: Montréal state: Quebec zip: H3N 1Y9 country: Canada name: Patricia LI role: CONTACT email: patricia.li@mcgill.ca name: Patricia Li role: PRINCIPAL_INVESTIGATOR name: Juan Carlos Chirgwin role: SUB_INVESTIGATOR lat: 45.50884 lon: -73.58781 facility: Montreal Children's Hospital city: Montréal state: Quebec zip: H4A 3J1 country: Canada name: Melissa Tachdjian role: CONTACT phone: 514-233-1873 email: melissa.tachdjian@rimuhc.ca name: Patricia Li role: CONTACT phone: 438-402-0510 email: patricia.li@mcgill.ca name: Patricia Li role: PRINCIPAL_INVESTIGATOR lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06373575 id: 2023-SR-891 briefTitle: IVC and Lung Ultrasound B-lines Guided Decongestion in Critically Ill ESKD Patients With Heart Failure overallStatus: ENROLLING_BY_INVITATION date: 2024-05-01 date: 2025-04-30 date: 2025-06-30 date: 2024-04-18 date: 2024-04-18 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: The objectives of this trial are to determine whether, in critically ill ESKD patients randomization to fluid removal guided by lung and inferior vena cava ultrasound, compared to standard care, leads to Improved pulmonary congestion (primary outcome); and safety (secondary outcome) in the short-term. conditions: End-stage Renal Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Lung and inferior vena cava ultrasound guidance name: Conventional protocol guidance measure: Improvement in pulmonary congestion score measure: Improvement in heart failure symptoms score measure: Total ultrafiltration volume measure: Mean ultrafiltration rate during prolonged hemodialysis measure: Fluid balance (total outflow - total inflow) measure: Lung B-line reduction measure: The change of width of inferior vena cava measure: Incidence of hypotension during prolonged hemodialysis measure: Blood pressure variability during the prolonged hemodialysis measure: In-hospital mortality measure: Length of hospital stay sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jiangsu Province Hospital city: Nanjing state: Jiangsu zip: 210029 country: China lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06373562 id: Wrestlers briefTitle: Effect of Hypoxic Exposure on Blood Variables in Elite Wrestlers overallStatus: COMPLETED date: 2013-12-02 date: 2013-12-18 date: 2013-12-18 date: 2024-04-18 date: 2024-04-18 name: Poznan University of Physical Education class: OTHER briefSummary: Twelve male wrestlers of the National Polish Team were observed in the study during the camp. The hypoxia group (n=6) participated in sports training and hypoxic exposure, while the control group (n=6) included wrestlers participating only in sports training. The hypoxic group lived and slept in hypoxic rooms. During the camp, all wrestlers followed the same training schedule and diet. In the blood were determined levels of creatine kinase (CK), C-reactive protein (hsCRP) concentration, nitric oxide (NO), morphology, reticulocytes, lipid profile, and ferritin. Also vascular endothelial growth factor (VEGF, VEGFR2, and VEGFR3), erythropoietin (EPO), angiopoietin (Ang 1, Ang 2), endothelial cell adhesion factor-1 (VCAM-1), Erythropoietin (EPO) and hypoxia-inducible factor 1 (HIF-1). Body weight composition was determined. conditions: Hypoxia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Wrestlers in H group were living in hypoxic rooms for 8-14h/d and between that they were participating in sports training. C group was participating in the same training protocol. primaryPurpose: DIAGNOSTIC masking: NONE count: 12 type: ACTUAL name: hypoxia measure: CK measure: hsCRP measure: HIF-1 measure: EPO measure: VEGF, VEGF 2, VEGF 3. measure: Ang 1, Ang 2 measure: VCAM-1 measure: blood count measure: lipid profile measure: ferritin sex: MALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373549 id: 2022/183-3896 briefTitle: Investigation of Myocardial Protection Efficacy of Cardioplegia Solutions Used in Open Heart Surgery overallStatus: COMPLETED date: 2022-12-08 date: 2023-07-24 date: 2023-07-24 date: 2024-04-18 date: 2024-04-18 name: Tamer cebe class: OTHER name: Istanbul University - Cerrahpasa (IUC) briefSummary: Cardioplegias are different pharmacokinetic solutions routinely used in cardiac surgery to protect the heart from ischemia and induce arrest. Various cardioplegia solutions (such as Bretschneider, del Nido, blood cardioplegia, crystalloid cardioplegia, St. Thomas) are used in clinical practice. There is no clear scientific data in the literature that demonstrates the superiority of one cardioplegia over the others. The choice of the appropriate cardioplegia depends on the surgeon's clinical experience and preference. In this study preferred the blood cardioplegia and del Nido cardioplegia, which are commonly used in clinic. Both cardioplegias have different advantages that contribute to their preference in clinical practice.
Blood cardioplegia is an autologous cardioplegia that includes physiological buffer systems, allowing for heart nourishment and containing native antioxidant systems. However, the need for repeated doses every 20 minutes after the initial application creates a disadvantage in terms of surgical comfort. On the other hand, del Nido cardioplegia is preferred by surgeons in complex cases due to its long application intervals. The adequacy of a single dose for up to 90 minutes after the initial application creates an advantage in terms of surgical comfort and surgical integrity. However, the content being predominantly electrolyte-based, containing 1:4 ratio of autologous blood, and the extended time of a single dose are disadvantages compared to blood cardioplegia in terms of heart nourishment and protection from ischemia. In addition to these different usage scenarios, the myocardial protective effects of cardioplegias on cellular redox homeostasis are also among the current research topics. Thesis project can contribute to the current literature and clinical practice on the cardioprotective advantages of cardioplegia solutions and the reasons for their preference in surgery. conditions: Cardiovascular Diseases conditions: Myocardial Reperfusion Injury studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2 type: ACTUAL name: Patients with coronary artery bypass surgery routine procedural administration of cardioplegia solutions name: Patients who underwent heart valve surgery without coronary artery disease routine procedural administration of cardioplegia solutions measure: Evaluation of the myocardial protective effects of different cardioplegia solutions through oxidative stress and redox signaling molecules. sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SBÜ. Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim ve Araştırma Hastanesi Erişkin Kalp ve Damar Cerrahisi Kliniği city: Istanbul state: Kadıköy zip: 34668 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06373536 id: LMU-RAD-01167 briefTitle: Comparison of MRI-PDFF to TAEUS FLIP Device to Estimate Liver Fat Fraction in Adults overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-09-01 date: 2024-04-18 date: 2024-04-18 name: Endra Lifesciences class: INDUSTRY briefSummary: Primary nonalcoholic fatty Liver disease (NAFLD) is an excess of fat in the liver (steatosis) that is not a result of excessive alcohol consumption or other secondary causes11. NAFLD is defined by the presence of hepatic fat content (steatosis) in ≥ 5% of hepatocytes and is currently the most common liver disease worldwide14 . Non-Alcoholic Fatty Liver Disease (NAFLD) is the world\'s most common liver disease and affects around 33% of the adult population.
Nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD), is a growing clinical concern associated with the increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome. NASH is characterized by the presence of hepatic steatosis, inflammation, and hepatocellular injury and is predicted to be the leading indication for liver transplantation by 20201. Patients with NASH have an increased risk of developing cirrhosis and its complications, such as ascites, variceal hemorrhage, hepatic encephalopathy, hepatocellular carcinoma, and liver failure. The prevalence worldwide of NAFLD in the general population is estimated at 20-35%2 . Around 2-3% of the population have NASH.
In patients with type 2 diabetes, the prevalence is even over 50% (55.5% globally, 68% in Europe). In Germany, the NAFLD prevalence was 23% in 2016 and will be around 26% in 2030. The prevalence of non-alcoholic alcoholic steatohepatitis (NASH), i.e. the progressive form of NAFLD, is estimated at 4% of the adult population in Germany and will increase to 6% by 2030. This means that NAFLD is already the most common chronic liver disease worldwide and one of the leading causes of liver-related complications (cirrhosis, decompensation, hepatocellular carcinoma, liver transplantation) and deaths. NAFLD and NASH are largely underdiagnosed worldwide. conditions: Steatosis of Liver studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 80 type: ESTIMATED name: Thermoacoustic imaging, MRI and Ultrasound imaging measure: Thermoacoustic Fat Measurements measure: Estimate Accuracy of Thermoacoustic Fat Fraction measure: Usability Metric measure: Estimate Operator Variability sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Klinikum der Universität München Großhadern Klinik und Poliklink für Radiologie city: München zip: 81377 country: Germany name: Monika Dienst, M.Sc. role: CONTACT phone: +49 89 4400 76642 email: monika.dienst@med.uni-muenchen.de name: Dirk-Andre Clevert, Prof. Dr. med. role: PRINCIPAL_INVESTIGATOR lat: 48.13743 lon: 11.57549 hasResults: False